AstraZeneca's camizestrant and Pfizer's vepdegestrant extended progression-free survival in trials in advanced ESR1-mutated breast cancer.

On the eve of hurricane season, Florida’s top disaster official promised Floridians that they will see no changes to the state’s hurricane response despite the turmoil at Federal ...

In May last year, the International Association of Anti-Corruption Authorities (IAACA), a 180-member-strong international anti-corruption organization currently headed by Danny Woo Ying-ming, ...

The Phase III trial showed that the new targeted therapy, inavolisib (Itovebi), provides significant survival benefits for ...

Allergies are a common and tricky problem in dogs and cats. Pets can be allergic to many of the same things people can, including pollen, chemicals, mold and food. Their ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and fulve ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall ...

Detailed price information for Roche Holding Ltd (RHHVF) from The Globe and Mail including charting and trades.

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

New Resource Highlights AITX's Solutions Portfolio, Operational Momentum, and Long-Term Vision Detroit, Michigan--(Newsfile ...

Autolus' CAR-T cell therapy for a rare and aggressive form of acute lymphoblastic leukaemia (ALL), Aucatzyl, has been ...